dea Archives | Psychedelic Spotlight

Tag Archive for: dea

Breaking: DEA Backs Off, Won’t Criminalize Two New Psychedelics

The DEA backs off announces they are withdrawing a proposed rule to ban the psychedelic drugs DOI and DOC, at least for now

The DEA is Attempting to Ban Two New Psychedelic Drugs

Policy

The DEA moves to ban two obscure psychedelic drugs, DOI and DOC, amidst ongoing calls to ease restrictions on psychedelic medicines

DEA Under Pressure from Terminally Ill “Right to Try” Psychedelic Advocates

Policy

The DEA is denying psilocybin therapy for dying patients despite the Right To Try Act. Here’s a timeline of the fight to access to psychedelic therapy for terminally ill patients

Shutterstock

The DEA Backs Down, Will Not Criminalize 5 Psychedelics

Policy

This week the DEA announced it would withdraw its plan to schedule 5 research psychedelics. But we shouldn't celebrate just yet

Judge Grants Hearing for Opposition to DEA Proposal to Criminalize 5 More Psychedelics

Policy

Biotech companies and researchers opposed to five more tryptamines becoming schedule 1 controlled substances will present their case this spring.

DEA Proposes Adding 5 Lesser-Known Psychedelics to Schedule 1 Controlled Substances

DEA Proposes Adding 5 More Psychedelics to Schedule 1 Controlled Substances

Policy

Agency argues these five tryptamines "have no known medical use," setting up a showdown with the emerging psychedelics industry.

Shutterstock.com

DEA Boosts Psychedelics Production (Again) to Meet Research Demand

Policy

Drug Enforcement Agency also addresses concerns from Native American Church regarding peyote poaching for mescaline research.

Shutterstock.com

DEA Quadruples Psilocybin Manufacturing for Research in Final 2021 Production Quotas

Policy

Drug Enforcement Agency also hugely boosts MDMA and DMT quotas “in response to the nationwide public interest in hallucinogenic controlled substances research.”

DEA Proposes Huge Increase to Psilocybin and Psilocin Quotas for Research Purposes

Policy

In its proposed revised 2021 quotas, the DEA suggests 4900% increase in the allowed quantities of psilocybin for research and clinical trial purposes.